Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal PGF Primary Antibody for IHC, ELISA - ABIN1585069
Bagley, Ren, Weber, Yao, Kurtzberg, Pinckney, Bangari, Nguyen, Brondyk, Kaplan, Teicher: Placental growth factor upregulation is a host response to antiangiogenic therapy. in Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Show all 3 Pubmed References
Mouse (Murine) Polyclonal PGF Primary Antibody for IF (p), IHC (p) - ABIN727220
Zhang, Zhao, Yuan, Wu, Jiang, Luo: Placenta growth factor contributes to cell apoptosis and epithelial-to-mesenchymal transition in the hyperoxia-induced acute lung injury. in Life sciences 2016
Show all 2 Pubmed References
Human Polyclonal PGF Primary Antibody for ELISA, WB - ABIN4238908
Cao, Ji, Qi, Rosin, Cao: Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. in Biochemical and biophysical research communications 1997
Human Polyclonal PGF Primary Antibody for ELISA, ICC - ABIN269292
Janér, Andersson, Haglund, Karikoski, Lassus: Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development. in Pediatrics 2008
Altered antiangiogenic state because of altered circulating PlGF leads to Preeclampsia.Ratio of sFlt1 (show FLT1 Antibodies)/PlGF correlates with Preeclampsia phenotypes.
Gestation-adjusted sEng, sFlt-1 and PlGF levels were 11%, 36%, and 30%, respectively, lower in women who later suffered miscarriage compared with unaffected pregnancies.
the optimal discrimination cut-off for each cytokine: sVEGFR-1 (2124.5pg/mL), IL-6 (show IL6 Antibodies) (40.2pg/mL), VEGF-A (show VEGFA Antibodies) (1060.1pg/mL), Angiopoeintin-2 (913.7pg/mL), uPA (show PRAP1 Antibodies) (248.1pg/mL), sHER-2/neu (show ERBB2 Antibodies) (5010pg/mL) and PLGF (93.4pg/mL). For the very first time, a novel cytokine profile associated with cancer metastasis to the paratracheal lymph nodes were reported.
The results of this study showed that PlGF expression significantly decreased at recurrence glioblastoma after adiotherapy-temozolomide.
From a clinical point of view, PLGF could be considered a valid diagnostic test for the detection of primary and recurrent bladder cancer. In patients with recurrent bladder cancer, plasma PLGF levels can differentiate individuals at risk of tumor recurrence.
Lower maternal PlGF concentration is associated with intrapartum fetal compromise and poorer condition of the newborn. Maternal PlGF levels may be useful as a component of a risk stratification tool for intrapartum fetal compromise in apparently 'low risk' term pregnancies prior to labour.
Study provides mechanistic and clinical evidence that decreased PLGF levels in the placenta after in utero alcohol exposure are associated to brain angiogenesis defects. Measurement of PLGF levels at birth in the placenta or the fetal blood may serve as a predictive marker for subsequent neurodevelopmental outcomes of exposed fetuses.
This effect was reversed by the addition of PlGF neutralising antibody to the conditioned medium.
Results show that both FLT1 (show FLT1 Antibodies) and PGF are overexpressed in the circulating tumor cells (CTCs) of patients with breast cancer. Also, a functional interaction of sFlt1 (show FLT1 Antibodies) and PGF was found, suggesting that their overexpression in tumor cells inhibits CTCs entering the peripheral blood.
Identify a novel cis (show CISH Antibodies)-acting sequence (-369 to -320) at the placental growth factor promoter, which was critical for mediating the basal and DLX3 (show DLX3 Antibodies)/GCM1 (show GCM1 Antibodies)-dependent PGF promoter activities.
PGF (show PTGFR Antibodies) deficiency is associated with impaired cerebral vascular development in mice.
PlGF inhibition attenuates PERK (show EIF2AK3 Antibodies) activation, likely by tempering hypoxia in HCC (show FAM126A Antibodies) via vessel normalisation. The UPR is able to regulate PlGF expression, suggesting the existence of a feedback mechanism for hypoxia-mediated UPR
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13 (show IL13 Antibodies).
Data indicate that placental growth factor (PlGF) is needed in the spleen to allow the activation of T cells and blood pressure raising.
Placental growth factor promotes differentiation of bone marrow-derived macrophages and enhanced vascular endothelial cell proliferation.
PLGF in LC cells induced macrophage polarization in vivo, and significantly promoted the growth of LC.
PLGF is upregulated in vascular cells in response to fluid shear stress.
Data suggests that PLGF may target islet endothelia to release growth factors activating PI3k signalling in beta cells to increase their proliferation. In Pre-Eclampsia, PLGF reduction impairs these processes resulting in gestational diabetes mellitus.
The neutrophil elastase (show ELANE Antibodies)-PlGF-JNK (show MAPK8 Antibodies)/PKCdelta (show PKCd Antibodies) pathway contributes to the pathogenesis of lung epithelial cell apoptosis and emphysema.
Study reports polymorphisms in the bovine PGF gene significantly associated with the maternal effect (show NLRP5 Antibodies) on stillbirth and calving ease in animals under selection.
placenta growth factor expression is regulated by both VEGF (show VEGFA Antibodies) and hyperglycaemia via VEGFR-2 (show KDR Antibodies)
This gene encodes a growth factor found in placenta which is homologous to vascular endothelial growth factor. Alternatively spliced transcripts encoding different isoforms have been found for this gene.
placental growth factor, vascular endothelial growth factor-related protein
, placenta growth factor
, placenta growth factor-like